Celine Halioua
Loyal's founder pursuing FDA approval for canine longevity drugs
Bio
Celine Halioua is the founder and CEO of Loyal, a biotech company developing longevity drugs for dogs and building the regulatory path that could, eventually, make aging itself a legitimate drug target for humans. In 2023 Loyal announced that the FDA's Center for Veterinary Medicine had accepted its 'reasonable expectation of effectiveness' technical package for LOY-001 — a notable regulatory milestone.
Background
Halioua began a DPhil at Oxford focused on genomics and neuroscience before leaving to work in longevity venture capital at what became Longevity Fund and Age1. She founded Loyal in 2019 with the explicit goal of building a company around veterinary longevity because the veterinary regulatory path allows 'extension of lifespan' as an achievable label claim in a way that human FDA pathways currently do not.
What They Do
Loyal is developing three main programs: LOY-001, a long-acting injectable targeting IGF-1 in large breed dogs; LOY-002, a daily pill aimed at metabolic aging markers in senior dogs of any size; and LOY-003, a chewable version of LOY-001. Halioua has been unusually conservative in her public communication — declining to oversell timelines, emphasizing regulatory realism, and distinguishing carefully between what the data show and what biohackers want it to show. Loyal has raised substantial venture capital, which creates commercial pressures that warrant ordinary skepticism without undermining the basic credibility of the program.
Research Record
Halioua is a founder rather than a publishing academic. Loyal's scientific contributions appear in regulatory filings and some conference presentations rather than peer-reviewed journals to date. This is appropriate for a preclinical / early-clinical stage biotech but means the evidence base is less accessible to outside review than for an academic lab.
Our Evidence Summary
Of the longevity-company founders in the public eye, Halioua's communication style is among the most evidence-calibrated. Her core strategic thesis — that dogs are a useful translational model and that the veterinary regulatory path can be used to validate aging-targeted drug development — is defensible and may turn out to be one of the more important moves in the field. The specific drug candidates remain early-stage, and their eventual efficacy is not yet proven; her public framing of them has been appropriately conservative.
Claim-by-Claim Evidence Review
Companion dogs are a meaningful translational model for human aging
Dogs share our environment, develop similar age-related diseases, and have compressed lifespans. The case for using them to validate longevity biology is stronger than for mice on several dimensions and is widely shared across the geroscience community.
Large breed dogs have elevated IGF-1 and shorter lifespans, making IGF-1 a plausible drug target
The inverse relationship between body size and lifespan in dogs, and its association with IGF-1 signaling, is well-documented in the canine genetics literature.
The FDA's 'reasonable expectation of effectiveness' milestone for LOY-001 is meaningful
It is a real regulatory step that allows a path toward conditional approval under the Minor Use and Minor Species framework. It is not the same as an approval, and Halioua has been careful to frame it that way publicly.
Loyal's drug candidates will be approved and improve healthspan in dogs
Pending clinical trial results and full FDA review. The regulatory path is real; the clinical outcomes are not yet established.
The veterinary regulatory pathway can inform a future human aging indication
Strategically reasonable — a successful canine longevity drug would be unprecedented and would influence regulatory thinking. But human translation remains a separate, larger question.
Dog trial results will translate to human healthspan benefits
Better than mouse extrapolation, but still extrapolation. Translation is a hypothesis to be tested, not a foregone conclusion.
The longevity field needs conservative, regulation-first communication
Not a scientific claim but a field-hygiene one. Halioua is an example of how longevity founders can communicate about early-stage biology without overselling — a posture that benefits the whole field.
Related Reading
The 12 Hallmarks of Aging: A Complete Guide
The 12 hallmarks of aging provide a scientific framework for understanding why we age and where interventions might slow or reverse the process.
Peptides for Longevity: A Science-Based Beginner's Guide
A science-based beginner's guide to peptides for longevity — Epitalon, GHK-Cu, BPC-157, MOTS-c — honest evidence and the regulatory reality.
Epigenetic Clocks: Measuring Your True Biological Age
Your birthday tells you your chronological age. Epigenetic clocks reveal your biological age — and why the difference matters for longevity science.